The 6th China International Import Expo has officially kicked off. How can multinational enterprises in China continue to penetrate the Chinese market and discover future prospects with the footsteps of "entering the Expo"?
Recently, Qi Xin, Vice President and General Manager of GSK (hereinafter referred to as "GSK"), and Ji Naxin, Vice President of GSK and Head of Clinical Research and Development in China, jointly accepted an interview with reporters from China News Agency.
Double acceleration of "landing" and "accessibility" of new drugs
Every year, we release innovative products or their new indications on the CIIE platform. After participating in the CIIE, multiple innovative products are quickly included in the medical insurance catalog of that year, "Qi Xin said." In the past three years, GSK has successfully listed six innovative drugs or indications in the national medical insurance catalog
At this Expo, GSK also had a number of new global products "debut" and "debut", which comprehensively demonstrated its important progress and innovative R&D strength in the four core treatment fields of infectious diseases, immune/respiratory diseases, tumors and HIV.
In the past few years, GSK has accelerated the launch of nearly 20 innovative vaccines and drugs in China, including multiple breakthrough therapeutic heavyweight products, and continuously expanded new indications. Qi Xin predicts that over the next three years, GSK China will have more than 5 new products or indications launched.
On November 6th, at the 6th China International Import Expo, GlaxoSmithKline fully demonstrated its important progress and innovative research and development capabilities in the four core treatment fields. Photographed by Tang Yanjun, a journalist from China News Agency
Jinbo Magnetic Field Gathers Collaborative "Moments"
In Qi Xin's view, GSK is not only a beneficiary of the development and transformation of China's healthcare industry, but also an active participant in the construction of China's healthcare industry. "We hope to actively integrate into China's reform and opening up agenda.
The CIIE not only has a 'spillover effect', but also a 'magnetic field effect', "Qi Xin said. GSK has been participating for many years and has reached cooperation with multiple local enterprises, foundations, associations, etc. to strengthen the 'integrated medical and prevention' ecosystem, promote the construction of a chronic disease management system and grassroots medical staff training. However, this is difficult to achieve quickly before having a 'CIIE stage'.
Qi Xin pointed out that China is the second largest pharmaceutical consumer market in the world, and there is still a large amount of unmet clinical demand, China has a huge population base, and with the active investment of the country in healthcare, we see that the market prospects in China are beyond doubt. As China enters a stage of high-quality development, the healthcare industry has ushered in a new period of development. China's rapid development in fields such as the Internet, artificial intelligence, big data, precision medicine, and biomedicine has also created many new opportunities and inspiration for the pharmaceutical industry
Increase investment to synchronize "Chinese R&D" with the global market
It is precisely by capturing multiple innovation opportunities under the vitality of the Chinese market that GSK has continuously increased its investment in China for many years. As early as 2007, GSK established its first research and development center outside of Europe and America in Shanghai, "said Ji Naxin. Currently, GSK has nearly 70 research projects worldwide, and Chinese research and development centers have achieved 90% synchronization with global research and development." Our goal is to achieve synchronization between China and global research and development. Even in some areas where China has special treatment needs, Chinese research and development needs to lead the world
This places extremely high demands on the cultivation of local talents, so GSK is actively cooperating with Chinese universities, research institutions, and other institutions to cultivate and introduce international management and research talents.
This is also due to China's consensus on talent cultivation and innovation in recent years, coupled with the continuous improvement of the market environment, which has provided a very good soil for our innovation research. This is also one of the 'spillover effects' of the CIIE, "Ji Naxin pointed out." This has continuously strengthened GSK's confidence in' Chinese innovation ', and the entry of new products into China will also continue to accelerate
As one of the first foreign-funded pharmaceutical companies to enter China after the reform and opening up, GSK's development in China continues to accelerate under the new opportunities.
In 2022, the new headquarters office of GSK China will be put into use in the front beach of Shanghai; GlaxoSmithKline Enterprise Management Co., Ltd. has been approved by the Shanghai Municipal Commission of Commerce to qualify as a "regional headquarters for multinational corporations". Since then, GSK has formed a joint force with the two major functional centers in Pudong - GSK China R&D Center and National Commercial Operations Center, comprehensively improving the level of GSK China headquarters.
We fully feel that in this hot land, we can accelerate innovation and reap the development dividends brought by the China International Import and Export Fair and the reform and opening up. This not only opens the door to opportunities for global enterprises, but also injects confidence into us to continue to deeply cultivate the Chinese market, "Qi Xin said.